Chris Marshall, who died on August 8 at age 66, was a world-renowned cell biologist best known for his pioneering contributions to oncogene research and to cell signaling via GTPases, especially to our understanding of tumor cell signaling through the Ras-Raf-Mek-Erk pathway. He spent the whole of his independent research career at the Chester Beatty Laboratories of the Institute of Cancer Research (ICR) in London, where he was Professor of Cell Biology and Head of the Division of Cancer Biology. Not long after his arrival at ICR in 1980, he established a close and superbly successful research partnership with Alan Hall, who predeceased him by three months (Cell 161, pp. 1239 (Cell 161, pp. -1240 (Cell 161, pp. , 2015 . It is poignant that Chris, who spoke so eloquently at Alan's funeral, was to follow so soon and that he succumbed to colon cancer, one of the tumors that most frequently carries RAS mutations. The international cancer research community keenly feels the dual loss of Chris and Alan.
Christopher John Marshall was born in Birmingham on January 19, 1949 to James and Lillian Marshall and later lived in Coventry, where he attended King Henry VIII School. His father was a works manager for Massey-Ferguson, the tractor manufacturers, and there was not a strong science tradition in his family. He won a scholarship to Churchill College, Cambridge to study natural sciences, specializing in genetics. As a graduate student, he joined Henry Harris's laboratory at the Sir William Dunn School of Pathology in Oxford, where he gained his DPhil in 1973. His doctoral studies concerned somatic cell genetics of hybrids between human and murine cells after Harris and Watkins developed an efficient method of cell fusion using inactivated Sendai virus. He used species-specific chromosome banding to examine chromosome segregation and studied the control of expression of ribosomal RNA in heterokaryons. His experience of somatic cell genetics served him well when he joined Sammy Franks' experimental pathology laboratory at the Imperial Cancer Research Fund Laboratories (now part of the Francis Crick Institute) and became interested in suppression of the malignant phenotype in normal-tumor cell hybrids and in markers of neoplastic transformation in human carcinomas. He continued this interest in tumor suppression during a second post-doctoral position with Ruth Sager at the Dana-Farber Cancer Center at Harvard Medical School.
Chris Marshall's illustrious career took off in 1980, when he joined the ICR to establish his own team. With the grant that he won from the Cancer Research Campaign, now part of Cancer Research UK (CRUK), he planned to continue studies of tumor suppression, which was still a nascent field. However, he soon joined forces with Alan Hall in Robin Weiss's laboratory to study oncogenes instead. Alan introduced the relatively new recombinant DNA techniques to the ICR, and the two of them embarked on a project searching for human oncogenes by DNA transfection into murine NIH 3T3 cells. This technique had recently been shown to work for murine tumors, and it was the natural next step to apply it to human tumors. Marshall and Hall tried DNA transfer from many human neoplastic cell lines without success and were on the point of abandoning the project when they obtained transformed cells using DNA from two human sarcoma cell lines. They successfully cloned the human gene responsible for cell transformation to reveal a novel member of the RAS oncogene family, NRAS. HRAS and KRAS were originally identified as retroviral oncogenes, but NRAS had not previously been characterized. The breakthrough exemplified two facets of Chris's aptitude for discovery: boldness to pursue a new avenue distinct from the original purpose of his research grant and perseverance.
The discovery of NRAS led to Chris's long-standing interest in cell signaling through the activation of small GTPases. About 12% of human tumors bear mutations in one of the three RAS genes that lead to constitutive signaling. Marshall and Hall made leading contributions to elucidating how Ras proteins transmit signals from the cell membrane through many steps to the nucleus. They played a major role in unraveling the signaling cascade that leads to cell proliferation via the Map-kinase pathway, and Chris's team showed that the p21 Ras protein must become farnesylated and thereby associate with membranes to function in the signaling pathway. They elucidated how Ras activates Raf, which acts on Mek and in turn activates Map-kinase, and showed that mutated NRAS results in overstimulation of this pathway.
Some years later, Chris employed his deep insight into the pathway to contribute to the first success of the Wellcome Trust Sanger Institute's Cancer Genome Project, in which Mike Stratton and his colleagues showed that the majority of melanomas tested carried a mutation in BRAF. Together with Richard Marais, he explored the biological consequences of the mutation and he returned to the bench to use his skills at transfection to demonstrate that the V600E mutant of BRAF is a transforming oncogene.
Chris was no ivory tower scientist. He adhered to Sydney Brenner's dictum that there is no real distinction between basic and applied research-only between good and mediocre research. He clearly saw the potential of exploiting the new knowledge of signal transduction for drug discovery. It was a source of great pleasure to him that four new classes of drug that target the pathway he did so much to elucidate have entered the clinic and that two of them are in widespread use.
During the past decade, Chris became interested in tumor cell motility and metastasis, and he extended his research into signaling pathways downstream of other GTPases such as Rac and Rho. He showed that these pathways control two alternate modes of cell movement, which differ in their requirement for extracellular proteolysis, and demonstrated the key role of the Rho effector kinase Rock. Ever alert to the translational agenda, one of his most recent papers reports that Rock inhibitors block melanoma cell motility, invasion, and metastasis in an animal model.
Tackling difficult problems came naturally to Chris, provided that they were potentially soluble. He exhibited great energy in both professional and recreational life, approaching science and cycling with equal enthusiasm. Vigorous scientific discussion with colleagues did not end upon leaving the lab for the day but often continued in neighboring pubs. During his 35 years at ICR, Chris took on many roles, most notably that of Director of Research. His forceful championing of the translational agenda and his insistence that such work could, and should, be of the highest quality was of great importance to the success of the ICR and its partner, the Royal Marsden Hospital. He was mentor to numerous young scientists who went on to successful research careers elsewhere, including Karen Vousden, Director of the CRUK Beatson Institute for Cancer Research in Glasgow, and Richard Marais, Director of the CRUK Manchester Institute, to name but two.
In contrast to enjoying the respect that he received from his scientific and academic peers, Chris did not regard himself as a pillar of the British ''establishment.'' When he joined the ranks of worthy people with an entry in Who's Who, he gave his ''club'' as Norwood Paragon Cycling, and it seems to us that that summed him up nicely.
Chris held his opinions strongly and could at times appear acerbic, yet he was a kind, loyal, and helpful colleague. He sat on various national and international panels with distinction. 
